S&P 500   4,539.79 (-0.82%)
DOW   34,500.07 (-0.40%)
QQQ   385.29 (-1.18%)
AAPL   163.49 (-0.16%)
MSFT   325.31 (-1.27%)
FB   307.24 (-1.01%)
GOOGL   2,856.51 (-0.10%)
AMZN   3,413.51 (-0.69%)
TSLA   1,048.60 (-3.32%)
NVDA   308.85 (-3.86%)
BABA   111.77 (-8.39%)
NIO   33.06 (-8.67%)
CGC   9.97 (-3.76%)
AMD   144.99 (-3.78%)
GE   93.31 (-2.02%)
MU   82.57 (-0.37%)
T   23.17 (+0.52%)
F   19.68 (-0.96%)
DIS   145.90 (-0.88%)
PFE   53.54 (+0.94%)
AMC   28.59 (-5.58%)
ACB   5.96 (-2.93%)
BA   198.46 (-1.94%)
S&P 500   4,539.79 (-0.82%)
DOW   34,500.07 (-0.40%)
QQQ   385.29 (-1.18%)
AAPL   163.49 (-0.16%)
MSFT   325.31 (-1.27%)
FB   307.24 (-1.01%)
GOOGL   2,856.51 (-0.10%)
AMZN   3,413.51 (-0.69%)
TSLA   1,048.60 (-3.32%)
NVDA   308.85 (-3.86%)
BABA   111.77 (-8.39%)
NIO   33.06 (-8.67%)
CGC   9.97 (-3.76%)
AMD   144.99 (-3.78%)
GE   93.31 (-2.02%)
MU   82.57 (-0.37%)
T   23.17 (+0.52%)
F   19.68 (-0.96%)
DIS   145.90 (-0.88%)
PFE   53.54 (+0.94%)
AMC   28.59 (-5.58%)
ACB   5.96 (-2.93%)
BA   198.46 (-1.94%)
S&P 500   4,539.79 (-0.82%)
DOW   34,500.07 (-0.40%)
QQQ   385.29 (-1.18%)
AAPL   163.49 (-0.16%)
MSFT   325.31 (-1.27%)
FB   307.24 (-1.01%)
GOOGL   2,856.51 (-0.10%)
AMZN   3,413.51 (-0.69%)
TSLA   1,048.60 (-3.32%)
NVDA   308.85 (-3.86%)
BABA   111.77 (-8.39%)
NIO   33.06 (-8.67%)
CGC   9.97 (-3.76%)
AMD   144.99 (-3.78%)
GE   93.31 (-2.02%)
MU   82.57 (-0.37%)
T   23.17 (+0.52%)
F   19.68 (-0.96%)
DIS   145.90 (-0.88%)
PFE   53.54 (+0.94%)
AMC   28.59 (-5.58%)
ACB   5.96 (-2.93%)
BA   198.46 (-1.94%)
S&P 500   4,539.79 (-0.82%)
DOW   34,500.07 (-0.40%)
QQQ   385.29 (-1.18%)
AAPL   163.49 (-0.16%)
MSFT   325.31 (-1.27%)
FB   307.24 (-1.01%)
GOOGL   2,856.51 (-0.10%)
AMZN   3,413.51 (-0.69%)
TSLA   1,048.60 (-3.32%)
NVDA   308.85 (-3.86%)
BABA   111.77 (-8.39%)
NIO   33.06 (-8.67%)
CGC   9.97 (-3.76%)
AMD   144.99 (-3.78%)
GE   93.31 (-2.02%)
MU   82.57 (-0.37%)
T   23.17 (+0.52%)
F   19.68 (-0.96%)
DIS   145.90 (-0.88%)
PFE   53.54 (+0.94%)
AMC   28.59 (-5.58%)
ACB   5.96 (-2.93%)
BA   198.46 (-1.94%)
NASDAQ:NLSP

NLS Pharmaceutics Stock Forecast, Price & News

$1.54
-0.10 (-6.10%)
(As of 12/3/2021 10:07 AM ET)
Add
Compare
Today's Range
$1.41
▼
$1.69
50-Day Range
$1.64
▼
$2.59
52-Week Range
$1.61
▼
$7.35
Volume
4,207 shs
Average Volume
1.35 million shs
Market Capitalization
$18.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive NLSP News and Ratings via Email

Sign-up to receive the latest news and ratings for NLS Pharmaceutics and its competitors with MarketBeat's FREE daily newsletter.


NLS Pharmaceutics logo

About NLS Pharmaceutics

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience, for the treatment of excessive daytime sleepiness and cataplexy; and Nolazol, for the treatment of ADHD. NLS Pharmaceutics AG was incorporated in 2015 and is based in Stans, Switzerland.

Headlines

Thinking about buying stock in NLS Pharmaceutics, Petros Pharmaceuticals, Palatin Technologies, TG Therapeutics, or Qualigen Therapeutics?
December 2, 2021 |  benzinga.com
NLS Pharmaceutics Soars on 'Long Covid' Fatigue Test Results
November 30, 2021 |  msn.com
NLS Pharmaceutics Soars on Long Covid Fatigue Test Results
November 30, 2021 |  finance.yahoo.com
NLS Pharmaceutics Announces Preclinical Results Confirming the Potential Benefit and Safety Profile of NLS-4 for Circadian Rhythm Dysregulation and Chronic Fatigue Syndrome in Long-Covid Model
November 30, 2021 |  finance.yahoo.com
NLS Pharmaceutics AG (NASDAQ:NLSP) Sees Large Increase in Short Interest
November 19, 2021 |  americanbankingnews.com
NLS Pharmaceutics' enrollment of its Phase 2a study to treat narcolepsy going 'very well'
November 4, 2021 |  proactiveinvestors.com
NLS Pharmaceutics CEO Issues Letter to Shareholders
November 1, 2021 |  finance.yahoo.com
NLS Pharmaceutics
October 21, 2021 |  benzinga.com
Leading the Charge to Develop the First Orexin-Targeted Therapy to Address Narcolepsy at its Root Cause
October 20, 2021 |  finance.yahoo.com
NLS Pharmaceutics Announces Preclinical Data Demonstrating the Potential of NLS-4 (Lauflumide) to Treat Chronic Fatigue Associated With Long-COVID
October 14, 2021 |  finance.yahoo.com
NLS Pharmaceutics AG: NLS Pharmaceutics to Participate in The Micro Cap Rodeo Fall Harvest Conference: Best Ideas from the Buy-side
October 2, 2021 |  finanznachrichten.de
Here's Why NLS Pharmaceutics (NASDAQ:NLSP) Must Use Its Cash Wisely
October 1, 2021 |  nasdaq.com
NLS Pharmaceutics (NASDAQ:NLSP) Will Have To Spend Its Cash Wisely
September 30, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NLSP
Previous Symbol
CUSIP
N/A
CIK
1783036
Web
www.nlspharma.com
Phone
N/A
Fax
41-41-618-8009
Employees
4
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.76) per share
Price / Book
-2.03

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.91
Quick Ratio
N/A

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
11,779,000
Free Float
N/A
Market Cap
$18.14 million
Optionable
Not Optionable

Company Calendar

Today
12/03/2021
Fiscal Year End
12/31/2021

MarketRank™

Overall MarketRank™

1.83 out of 5 stars

Medical Sector

809th out of 1,391 stocks

Pharmaceutical Preparations Industry

381st out of 669 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












NLS Pharmaceutics (NASDAQ:NLSP) Frequently Asked Questions

Is NLS Pharmaceutics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NLS Pharmaceutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NLS Pharmaceutics stock.
View analyst ratings for NLS Pharmaceutics or view top-rated stocks.

Are investors shorting NLS Pharmaceutics?

NLS Pharmaceutics saw a increase in short interest in the month of October. As of October 29th, there was short interest totaling 92,600 shares, an increase of 51.6% from the October 14th total of 61,100 shares. Based on an average trading volume of 273,600 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1.5% of the company's stock are short sold.
View NLS Pharmaceutics' Short Interest.

What price target have analysts set for NLSP?

3 equities research analysts have issued twelve-month price objectives for NLS Pharmaceutics' stock. Their forecasts range from $8.00 to $12.00. On average, they anticipate NLS Pharmaceutics' share price to reach $10.67 in the next year. This suggests a possible upside of 592.6% from the stock's current price.
View analysts' price targets for NLS Pharmaceutics or view top-rated stocks among Wall Street analysts.

Who are NLS Pharmaceutics' key executives?

NLS Pharmaceutics' management team includes the following people:
  • Mr. Alexander Zwyer M.B.A., Pres, CEO & Director (Age 52)
  • Mr. Subhasis Roy M.B.A., Interim Chief Financial Officer (Age 52)
  • Dr. Silvia Panigone, Chief Operating Officer (Age 49)
  • Mr. Eric Konofal M.D., Ph.D., Interim Chief Scientific Officer (Age 54)
  • Dr. Christian C. Wenger L.L.M., Dr. iur., Ph.D., LL.M., Gen. Counsel (Age 57)
  • Ms. Sharon Keys, Head of Regulatory Affairs
  • Mr. Herve Girsault M.A., M.B.A., MA, MBA, Head of Bus. Devel. (Age 61)

When did NLS Pharmaceutics IPO?

(NLSP) raised $20 million in an initial public offering (IPO) on Friday, January 29th 2021. The company issued 3,600,000 shares at a price of $5.00-$6.00 per share. Maxim Group LLC served as the underwriter for the IPO and Brookline Capital (A division of Arcadia Securities) was co-manager.

What is NLS Pharmaceutics' stock symbol?

NLS Pharmaceutics trades on the NASDAQ under the ticker symbol "NLSP."

Who are NLS Pharmaceutics' major shareholders?

NLS Pharmaceutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include UBS Group AG (0.53%), Two Sigma Advisers LP (0.23%), Citadel Advisors LLC (0.17%), Geode Capital Management LLC (0.12%) and Two Sigma Securities LLC (0.09%).

Which institutional investors are buying NLS Pharmaceutics stock?

NLSP stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG, Two Sigma Advisers LP, Geode Capital Management LLC, Two Sigma Securities LLC, and Citadel Advisors LLC.

How do I buy shares of NLS Pharmaceutics?

Shares of NLSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NLS Pharmaceutics' stock price today?

One share of NLSP stock can currently be purchased for approximately $1.54.

How much money does NLS Pharmaceutics make?

NLS Pharmaceutics has a market capitalization of $18.14 million.

How many employees does NLS Pharmaceutics have?

NLS Pharmaceutics employs 4 workers across the globe.

What is NLS Pharmaceutics' official website?

The official website for NLS Pharmaceutics is www.nlspharma.com.

Where are NLS Pharmaceutics' headquarters?

NLS Pharmaceutics is headquartered at ALTER POSTPLATZ 2, STANS V8, CH-6370.


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.